Since late 1880, Sanofi, Synthélabo, Hoechst, Rhône-Poulenc Rorer led to the creation of Sanofi. These companies have accumulated over a century of experience in health, with a core concern of innovation to meet the evolution of society and the needs of patients. Today, Sanofi and its 100,000 employees are dedicated to make a difference on patients’ daily life, wherever they live, and enable them to enjoy a healthier life. In 2011 with acquisition of Genzyme, Sanofi’s Rare Disease portfolio developed immensely. The Vaccine development sector is known as Sanofi Pasteur and is one of the leading companies in the field of vaccine development in the world. Sanofi has 79 manufacturing sites in 36 countries and provides healthcare solutions in more than 170 countries around the world.
Founded in Boston in 1981, Genzyme rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for Rare Genetic Disorders.
Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities.
Genzyme became part of Sanofi in 2011 as the specialty care global business unit. While continuing to focus on Rare Diseases, it also established itself as a leader in the field of Multiple Sclerosis. In 2016, its focus expanded to include Sanofi’s programs in Oncology and Immunology.
Sanofi Genzyme ambition is to be the industry leader in specialty care. It currently provides more than 20 treatments to patients globally, with many potential new therapies being studied in clinical trials in Sanofi laboratories.
Driven by its commitment to patients, it strives to develop strong relationships with the patient communities, listening to their perspectives so that it can truly understand their needs. These collaborations continue to guide and motivate it to push the boundaries of medicine and technology to develop new and better therapies where none existed before.
Sanofi Pasteur believes in a world where no one suffers or dies from a vaccine preventable disease. Its vaccines help protect as many as half a billion lives each year against life-threatening infectious diseases at every stage of life. With its 15000 employees worldwide, they seek to extend the protective power of vaccination to new infectious diseases while continuously improving existing vaccines to enhance health and well being. It has a diverse portfolio of high-quality vaccines for children, adolescents and adults, including Influenza, Meningitis, Travel and Endemic Diseases. Sanofi Pasteur is a world leader in Influenza and Pediatrics Vaccines, and the first worldwide supplier of Polio Injectable Vaccine.